BridgeBio's unique structure creates dedicated subsidiaries for each program. This empowers small, focused teams closest to the science to make key decisions—"play calling on the field"—without layers of bureaucracy. This model dramatically accelerates development, leading to unprecedented output of new drugs.

The transition from a leadership role at a large pharma company like Gilead to a biotech CEO involves a massive shift in scope. Instead of managing one large function with a large team, a biotech CEO is hands-on with every aspect of the company, from science to finance.

The traditional pharma leadership model focused on minimizing risk through tight, linear control is no longer competitive. The future requires a shift to agile coordination, allowing leaders to reallocate priorities quickly in a data-driven, connected way.

The motivation for a senior leader to leave a stable pharma career for a risky biotech is often mission-driven. The primary driver is the ability to leverage a focused technology to address patient unmet needs with greater speed, bypassing the complexities of large organizations. It's about a clearer and quicker line-of-sight to the clinic and to patients.

The primary operational difference between biotech and big pharma isn't just budget size, but how resource constraints force radical prioritization. The entire biotech organization must align on three or four critical, needle-moving goals tied to the next financing catalyst, a level of focus often diffused in larger companies.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

The transition from academic scientist to biotech CEO involves a critical mindset shift. In academia, ideas and knowledge are the primary capital. In the resource-intensive biotech world, time is the scarcest and most valuable asset, demanding parallel execution.

After a long tenure in big pharma, executives may feel a need to transition to biotech to avoid being typecast. The move allows them to apply their extensive experience in a more agile environment and prove their versatility, preventing career stagnation within a single corporate structure.

To avoid bureaucratic slowdowns as it scales, Legend Biotech maintains its nimble "startup" culture by constantly focusing the team on patient needs. This patient-centricity, combined with efficient leadership decision-making, ensures the company operates with speed and purpose despite its large size.